The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Disparities in mortality trends and age-related outcomes in older adults with DLBCL
Sairah Ahmed, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the disparities in mortality trends and age-related outcomes in older adults with diffuse large B-cell lymphoma (DLBCL). She notes that older patients tend to have worse outcomes and highlights the need to reassess treatment strategies to improve outcomes for this patient population. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is a project done by Saad Nasser, who is a medical student, and it’s really looking at the disparities in patients who have large B-cell lymphoma and the differences in age-related mortality. And what it demonstrates is that older patients tend to have worse outcomes. Now that may be indicative of the bias of treating those patients where they receive therapy and other comorbidities that may limit curative intent treatment...
This is a project done by Saad Nasser, who is a medical student, and it’s really looking at the disparities in patients who have large B-cell lymphoma and the differences in age-related mortality. And what it demonstrates is that older patients tend to have worse outcomes. Now that may be indicative of the bias of treating those patients where they receive therapy and other comorbidities that may limit curative intent treatment. But I think it kind of includes a broader question of how patients are being treated throughout the country over time and with older age and how we could potentially do better with potentially less chemotherapy regimens and more novel therapy and directed therapy for those patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
